Clinical Trials Logo

Cardiovascular Diseases clinical trials

View clinical trials related to Cardiovascular Diseases.

Filter by:

NCT ID: NCT04849195 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Comparison of Different Feature Engineering Methods for Automated ICD Coding

Start date: March 1, 2021
Phase:
Study type: Observational

Using traditional machine learning classifiers, this study targets on comparing bag-of-words, word2cec and roberta on automated ICD coding related to cardiovascular diseases in Chinese corpus.

NCT ID: NCT04845750 Not yet recruiting - Clinical trials for Cardiovascular Diseases

The RODEO Micro Mapping Catheter in Cryoablation Procedures

RODEO-MaPS
Start date: April 14, 2021
Phase: N/A
Study type: Interventional

This clinical investigation evaluates the feasibility of the Rodeo Micro Mapping Catheter in combination with cryoablation ssystem (sclerotherapy of muscle tissue of the heart by freezing) in patients with atrial fibrillation (permanent atrial fibrillation excepted). Further aims of this study are the evaluation of safety of the device and average procedure and fluoroscopy times.

NCT ID: NCT04843891 Not yet recruiting - Cancer Clinical Trials

Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.

Start date: July 6, 2021
Phase: Phase 1
Study type: Interventional

To evaluate the safety of [64Cu] Macrin and its whole-body distribution, metabolism, pharmacokinetics, and radiation burden in healthy volunteers. To detect [64Cu]-Macrin accumulation in sites of disease in subjects with cancer, sarcoidosis or myocardial infarct.

NCT ID: NCT04838457 Not yet recruiting - Hypertension Clinical Trials

Telehealth Treatment of Veterans With Alcohol Misuse at Risk for Cardiovascular Disease

ACME-TM
Start date: October 1, 2021
Phase: N/A
Study type: Interventional

The primary objective of this project is to refine a cognitive-behavioral intervention for comorbid alcohol misuse and modifiable CVD risk with diverse stakeholder input, so that the intervention can be deployed within existing VA systems. The intervention will deliver telehealth CBT for alcohol misuse, tailored and timely text messages facilitating clinical traction with CVD risk reduction, and a telehealth coaching call to transition focus of treatment targets. The primary hypotheses of this study are that the developed intervention will be feasible to deliver, acceptable to Veterans and clinicians, and show signs of reducing alcohol misuse and increasing behaviors associated with cardiovascular health.

NCT ID: NCT04836117 Not yet recruiting - Clinical trials for Impact of Providing Personalized Proteomic Health Insights to Patients

Evaluating the Impact of SomaSignal Tests on Medical Management and Change in Risk in Patients at Higher Risk of Cardiovascular Disease: A Feasibility and an Adaptive Implementation Study

SomaSignal
Start date: May 1, 2021
Phase: N/A
Study type: Interventional

Feasibility Study Informed consent will be obtained using an IRB-approved form. The first 12 consenting patients will be placed in the planned assessment group for feasibility and will not be randomized. These participants will undergo visits and blood draw collection at 3 months. They will be informed of their SomaSignal Test results at baseline and 3 months. Recommendations for any medical management changes will be made based on an understanding of those results. Randomized Study The succeeding 200 participants will be randomized using permuted mixed block randomization, in a 2:1 ratio, i.e., 2 participants to Group 1 (informed of their test results) and 1 participant to Group 2 (uninformed of their test results). At enrollment, and for 6 months thereafter, clinical information will be obtained from each participant's medical records, and/or directly from the participant during procedures, treatments, study-specific visits, and/or follow-up visits. Data collected for the study will have data linkage at SomaLogic, Inc., where data analysis will be done. At baseline and 6-months (+30 days) post-enrollment, patients will undergo a patient visit and blood collection. Blood will be collected as a stand-alone sample collection, or when other ordered lab work is done, or from access lines inserted during a usual or specialized care. Samples will be sent to the Intermountain Central laboratory for clinical testing. A sample will also be processed and shipped to SomaLogic, Inc. for analysis at baseline and 6 months. For the informed arm, the SomaSignal Test reports will be provided at the time they are available (2 to 4 weeks after the blood draw). Any recommended changes in medical management will be recorded in the case report forms and will be verified by the Principal Investigator. For the uninformed arm, the SomaSignal Test results will not be provided to the study team until after the 6-month post-test visit. Adjustments, if any, would be made to the participant's management at that time.

NCT ID: NCT04834843 Completed - Clinical trials for Coronary Artery Disease

Temporal Trends of COronary Artery Disease and PEripheral Artery Disease (COPE) in Korea

COPE registry
Start date: January 1, 2009
Phase:
Study type: Observational

Cardiovascular disease (CVD) is caused by atherosclerosis of the artery and is classified into coronary artery disease, cerebrovascular disease, and peripheral arterial disease, depending on the location of the artery and the target organs. However, since CVD share a similar pathophysiology and the probability of incidence of other CVD in CVD patients is very high. It is thought that CVD incidence and mortality can be reduced by predicting the degree of incidence of other CVD in CVD patients. The aim of this study is to investigate the incidence and mortality of other CVD diseases in CVD patients.

NCT ID: NCT04834089 Not yet recruiting - Cancer Clinical Trials

Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases

SOROCOV
Start date: May 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due to underlying medical conditions to determine the utility of an equine heterologous serum anti-SARS-CoV-2 to avoid progression to a severe COVID-19

NCT ID: NCT04833712 Recruiting - Clinical trials for Cardiovascular Diseases

Stereotactic Radioablation for the Treatment of Refractory Atrial Fibrillation

RAD-AF
Start date: May 10, 2021
Phase: N/A
Study type: Interventional

The study aims to investigate the short-term (3 months) and intermediate-term (12 months) safety and preliminary efficacy of stereotactic radiotherapy for pulmonary vein isolation to treat refractory atrial fibrillation.

NCT ID: NCT04830696 Recruiting - Heart Failure Clinical Trials

3D ECG for Detection of Cardiomyopathy

Start date: March 14, 2021
Phase:
Study type: Observational

There is existing data in the literature that suggests an additional predictive value of three dimensional ECG with respect to the presence of electrical abnormalities and for an existing cardiac disease. Especially regarding patients who suffered from a myocardial infarction in the past (post MI patients), evidence has been provided for a potential association of 3D repolarisation abnormalities and incidence of sudden cardiac death (SCD). In addition, there is some vague evidence of so called 3D ECG and prediction of coronary artery disease. This 3D ECG device is using the technology of 3D ECG vector loops and is assessing the variability of these ECG vector loops in the 3-dimensional space. Based on these data, the parameters of 3D ECG are suggested to carry certain value to predict or to identify individuals already suffering from a cardiac disease or being at risk experiencing a cardiac event in the future. In this context we performed a preliminary study with 3D-ECG device in healthy volunteers evaluating the robustness of this method with respect to reproducibility, intra- and intra-observer variability which could be confirmed. We thus postulate that the 3D ECG technology might bear the potential to serve as a sufficient screening method for diagnosing cardiomyopathy in patients with an unknown heart failure etiology.

NCT ID: NCT04828655 Active, not recruiting - Hypertension Clinical Trials

Analysis of Bioparametric Measures for Correlating Daily Habits and Reducing Blood Pressure

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

To study the effects of the use of a mobile application plus recommendations based on a Mediterranean diet on the intake of micronutrients from natural sources (not drugs) on health indicators, cardiovascular parameters (blood pressure...), physical condition and body composition in a Spanish adult population.